SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group (CRDO) is experiencing a significant surge following its pre-announcement of substantially increased revenue guidance for the current quarter and strong fiscal year growth projections. This positive outlook is fueling investor excitement, with many anticipating further upside as the company, a key player in AI data center connectivity, continues to benefit from accelerating hyperscaler capital expenditures amidst ongoing discussions about its technological positioning.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending as the FDA issued a Complete Response Letter for its RGX-121 gene therapy for Hunter syndrome, citing trial design concerns and an ongoing clinical hold extended due to a potential adverse event in a related gene therapy utilizing the same AAV vector platform. The community is expressing significant disappointment over the rejection and its impact on RGNX's valuation, while also questioning the FDA's scrutiny of gene therapies and celebrating gains from short positions.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is rallying on community excitement around imminent EU approval for its cancer therapeutic, Anktiva, and intensified discussions of an 'Immunotherapy 2.0' partnership with Saudi Arabia for broad cancer indications. Investors are anticipating a significant short squeeze, validating the company's undervalued platform against recent industry acquisitions and its mission to deliver 'unstoppable' cancer treatments.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending as recent weak guidance for the coming quarter has driven a sell-off and ignited community debate over decelerating automotive and industrial demand. While bears foresee further drops, bulls are underscoring the company's strategic pivot to AI data centers with a significant Nvidia partnership and a large share repurchase program.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending following its earnings report, sparking community discussion over a notable stock decline despite positive EPS growth and reaffirmed guidance, with many attributing the dip to revenue shifts while maintaining strong long-term confidence in its extensive backlog of critical government, defense, and nuclear contracts.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is actively discussed after its latest earnings surpassed expectations with record revenue and profitability, propelled by its AI initiatives including Uma. While many anticipate a short squeeze and highlight undervaluation in the evolving gig economy, others voice frustration over the stock's muted response and concerns about client growth in an AI-driven landscape.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is a top trending stock, buoyed by recent analyst upgrades and its pivotal role in the rapidly expanding AI data center infrastructure. The community is highly focused on its essential high-speed connectivity solutions, strategic optical technology acquisitions, and potential for significant growth driven by hyperscaler spending.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

With its upcoming earnings report sparking significant options activity, Fiserv (FISV) is trending amidst a polarized community debate: optimists highlight recent insider and institutional buying alongside deep undervaluation, while skeptics worry about the stock's persistent weakness and broader fintech sector headwinds exacerbated by AI disruption concerns.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is trending sharply lower following the abrupt departures of its CFO and General Counsel amid an accounting review and delayed financial filings, sparking intense community discussion about whether the significant sell-off is an extreme overreaction or indicative of severe internal control issues.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

AgomAb Therapeutics NV - ADR

AGMB is experiencing heightened attention as a new IPO amid extreme volatility, with community discussions largely focused on its low float potentially fueling a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TD Waterhouse Canada Inc. Takes $2.03 Million Position in Carlsmed, Inc. $CARL

TD Waterhouse Canada Inc. bought a new stake in Carlsmed, Inc. (NASDAQ:CARL - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 152,242...

Teacher Retirement System of Texas Purchases Shares of 175,000 Carlsmed, Inc. $CARL

Teacher Retirement System of Texas acquired a new position in Carlsmed, Inc. (NASDAQ:CARL - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange...

Carlsmed (NASDAQ:CARL) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Carlsmed from a "hold" rating to a "sell" rating in a report on Saturday...

CARL Launches Aprevo Cervical Platform for Personalized Spine Surgery

Carlsmed launches personalized aprevo cervical platform with early cases and new reimbursement support driving momentum in spine surgery.

Carlsmed (NASDAQ:CARL) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded Carlsmed from a "sell" rating to a "hold" rating in a report on Saturday...

Truist Financial Reaffirms Buy Rating for Carlsmed (NASDAQ:CARL)

Truist Financial reissued a "buy" rating and issued a $20.00 price objective (up previously from $18.00) on shares of Carlsmed in a research note on Friday...

Carlsmed (NASDAQ:CARL) Announces Earnings Results, Beats Expectations By $0.05 EPS

Carlsmed (NASDAQ:CARL - Get Free Report) posted its earnings results on Thursday. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.05...

Goldman Sachs has started coverage of Carlsmed with a ‘Buy’ rating and a $19 price target, suggesting about 35% upside from recent levels.The research firm’s&nbsp;analyst David Roman said the firm sees “meaningful upside” for the stock thanks to Carlsmed’s differentiated technology platform and asset-light business model,&nbsp;the Fly reported.He pointed to the company’s&nbsp;salesforce expansion, its planned 2026 launch in cervical spine procedures, and a steady flow of new clinical data as important revenue drivers.The call comes after several recent milestones. Earlier this month, the Centers for Medicare &amp; Medicaid Services (CMS) granted New Technology Add-On Payment (NTAP) reimbursement for cervical fusion procedures using Carlsmed’s aprevo implants.&nbsp;Starting&nbsp;in&nbsp;October, through the NTAP program, hospitals performing these procedures will be eligible for up to an additional $21,125 in reimbursement on top of standard payments.Carlsmed also reported the first cervical procedure with its aprevo device in July at UC San Diego Health, showing progress toward a U.S. launch targeted for 2026. The company’s technology is already approved for lumbar fusion surgery and uses AI-driven planning tools to design personalized implants for patients.The company had its initial public offering on July 23, raising $100.5 million at an IPO price of $15 per share. The shares dropped 3.3% on the first day of trading, closing at $14.50, valuing the company at about $384 million.&nbsp;Since then,&nbsp;<a href="https://stocktwits.com/symbol/CARL">Carlsmed’s shares</a>&nbsp;have fallen&nbsp;6.3% year-to-date. On Friday, the stock closed 2.7% lower at $13.58 before ticking up 0.5% after hours to $13.65.Carlsmed, founded in 2018, has drawn backing from B Capital Group and US Venture Partners, which together own nearly half the company. Co-founder and Chief Executive Michael Cordonnier holds a smaller stake.&nbsp;In the first quarter of 2025, the company lost $5.7 million on $10.2 million in revenue, compared with a loss of $5.4 million on $5.1 million in revenue a year earlier.On Stocktwits, retail sentiment for Carlsmed was ‘bearish’ by late Sunday, worsening from the ‘neutral’ mood seen a day ago, amid ‘normal’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Goldman Sachs has started coverage of Carlsmed (CARL) with a ‘Buy’ rating and a $19 price target. (Photo credit: Getty Images)

Carlsmed Stock Down 6% Since IPO But Goldman Bullish And Predicts 35% Upside Potential — Retail Traders Stay Bearish

The company’s July IPO raised $100.5 million but shares have slipped since, closing Friday at $13.58 before edging up in after-hours trade.

Equity

Carlsmed, Inc. engages in the development of AI based technology solutions to the medical industry. Its solutions are utilized as an information database for surgeons using traditional surgical techniques. The company was founded by Mike Cordonnier and Niall Casey and is headquartered in Carlsbad, CA.

Carlsmed Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

CARL
Carlsmed Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CARL News

CARLCarlsmed Inc